Literature DB >> 2139665

Prothymosin-alpha enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis.

C N Baxevanis1, C Sfagos, E Anastasopoulos, G J Reclos, M Papamichail.   

Abstract

Monocytes from patients with multiple sclerosis (MS) express decreased numbers of class II major histocompatibility complex (MHC) antigens in peripheral blood and are poor stimulators in the autologous mixed lymphocyte reaction (autoMLR). We assessed the effect of prothymosin-alpha (ProT alpha) on the expression of MHC class II antigens by monocytes. Immediately after isolation, monocytes were analyzed for MHC class II antigen expression using a radiolabelled monoclonal antibody specific for a monomorphic determinant on HLA-DR antigens. After incubation with ProT alpha we observed significant increases in HLA-DR antigens on MS monocytes (1.5- to 4-fold increase compared to freshly isolated monocytes). Kinetic analysis revealed that enhancement peaked after 2 days of incubation with ProT alpha. The increase in HLA-DR antigen on MS monocytes resulted in the restoration of the deficient autoMLR in MS patients. This is the first demonstration suggesting a link between HLA-DR antigen expression and cellular immune defects in MS. The significance of low autoMLR responses for T suppressor levels in MS patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139665     DOI: 10.1016/0165-5728(90)90063-s

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha.

Authors:  M Papanastasiou; C N Baxevanis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.

Authors:  Yossi Gilgun-Sherki; Yael Barhum; Daphne Atlas; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 3.  Roles of thymosins in cancers and other organ systems.

Authors:  Changyi Chen; Min Li; Hui Yang; Hong Chai; William Fisher; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

4.  Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Authors:  C N Baxevanis; A D Gritzapis; G Spanakos; O E Tsitsilonis; M Papamichail
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

5.  Potential Role of Thymosin-alpha1 Adjuvant Therapy for Glioblastoma.

Authors:  Arno Sungarian; Deus Cielo; Prakash Sampath; Nathaniel Bowling; Peter Moskal; Jack R Wands; Suzanne M de la Monte
Journal:  J Oncol       Date:  2010-01-11       Impact factor: 4.375

Review 6.  Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.

Authors:  Martina Severa; Jing Zhang; Elena Giacomini; Fabiana Rizzo; Marilena Paola Etna; Melania Cruciani; Enrico Garaci; Michael Chopp; Eliana Marina Coccia
Journal:  Mult Scler Relat Disord       Date:  2018-10-02       Impact factor: 4.339

7.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.